drugset / Trial / NCT07044544
Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety of adding Decitabine and Venetoclax to patients undergoing reduced intensity allogenic transplantation for treatment of hematologic malignances with Fludarabine and Melphalan.
Timeline
- Start
- 2025-07-17
- Primary completion
- 2026-12
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Decitabine | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Venetoclax | Small molecule | 200 mg | Oral |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |
| Background | G-CSF | Protein / enzyme biologic | 5 ug/kg | Subcutaneous |